Patient case (clinical description): A 3-year-old girl is brought to the clinic by her parents for assessment of her short stature. Physical examination reveals short limbs and a relatively large head. She has a flat nasal bridge and a small midface. The girl's father exhibits similar physical features; however, her mother looks normal. The genetic testing reveals an autosomal dominant point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene consistent with achondroplasia in both father and the child. The girl has not received any treatment yet, and it is her first visit after immigration to the US. The other mental and developmental examinations are unremarkable.

Patient's own account: I just brought my little 3-year-old girl to the clinic to have her checked up by the doctor. I was worried sick because she was smaller than her classmates. The lovely doctor performed a physical exam and she told me that she has short limbs and a larger head. My girl also has a flat nasal bridge and a small midface. My baby just has the face of her father, unlike me! They performed some genetic testing on my child and my husband and found out that both my husband and her have a mutation of the FGFR3 gene, which led the doctor to diagnose them with dwarfism. My baby never received any treatment and it was our first visit to the doctor since we arrived in the US. The other tests regarding her mental and physical development were perfectly fine.

Clinical trial: Web-based Adherence Information Integrated Nurse-led Monitoring Clinic

Eligibility criteria:
Inclusion Criteria:

          -  All patients who receive easypod GH of age 1-14 years will be approached for consent
             to participate in the study. Patients may have any valid cause for short stature.
             These may include children with

          -  isolated growth hormone deficiency

          -  multiple pituitary hormone deficiencies

          -  non-growth hormone deficient conditions such as

          -  Small for gestational age with postnatal failure of height gain

          -  chronic renal failure and

          -  Turner syndrome. Patients will be recruited to the study irrespective of diagnosis and
             will not be stratified by diagnosis at entry to the study. However, in analysis of
             data, subgroup analysis may be performed on groups such as those with isolated growth
             hormone deficiency, dependent on the frequency of recruitment.

        All patients will be identified at the start of the study. A one month period will be
        considered before the study commences to contact families for potential recruitment. Each
        patient will remain in the study for 12 months. The active study duration will be 18 months
        whereby all eligible patients will be recruited and followed up for a 12 month period. This
        period will be followed by a buffer period to gather necessary data for analysis.

        Exclusion Criteria:

          -  Patients on growth hormone treatment but using other growth hormone devices Patients
             who are younger or older than the age limits.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 1 Year old.
Subject must be at most 14 Years

Eligibility (NLI label): Contradiction